CN111393414B - 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物 - Google Patents

用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物 Download PDF

Info

Publication number
CN111393414B
CN111393414B CN202010152637.8A CN202010152637A CN111393414B CN 111393414 B CN111393414 B CN 111393414B CN 202010152637 A CN202010152637 A CN 202010152637A CN 111393414 B CN111393414 B CN 111393414B
Authority
CN
China
Prior art keywords
compound
piperidine
methyl
sulfonyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010152637.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111393414A (zh
Inventor
J·奥斯洛布
D·奥贝勒
J·金
R·麦克道尔
宋永红
A·斯兰
钟民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Priority to CN202010152637.8A priority Critical patent/CN111393414B/zh
Publication of CN111393414A publication Critical patent/CN111393414A/zh
Application granted granted Critical
Publication of CN111393414B publication Critical patent/CN111393414B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202010152637.8A 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物 Active CN111393414B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010152637.8A CN111393414B (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22
US62/106,571 2015-01-22
CN201680017126.7A CN107428719B (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
PCT/US2016/014365 WO2016118774A1 (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
CN202010152637.8A CN111393414B (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680017126.7A Division CN107428719B (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物

Publications (2)

Publication Number Publication Date
CN111393414A CN111393414A (zh) 2020-07-10
CN111393414B true CN111393414B (zh) 2024-05-07

Family

ID=55275230

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010152637.8A Active CN111393414B (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
CN201680017126.7A Active CN107428719B (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
CN202410163448.9A Pending CN118164961A (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201680017126.7A Active CN107428719B (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
CN202410163448.9A Pending CN118164961A (zh) 2015-01-22 2016-01-21 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物

Country Status (36)

Country Link
US (1) US9925177B2 (enExample)
EP (2) EP4234017A3 (enExample)
JP (1) JP6712275B2 (enExample)
KR (3) KR102585550B1 (enExample)
CN (3) CN111393414B (enExample)
AU (4) AU2016209200B2 (enExample)
BR (1) BR112017015627B1 (enExample)
CA (1) CA2974370C (enExample)
CL (1) CL2017001871A1 (enExample)
CO (1) CO2017008398A2 (enExample)
CR (1) CR20170370A (enExample)
DK (1) DK3247707T3 (enExample)
DO (2) DOP2017000166A (enExample)
EA (1) EA036923B1 (enExample)
EC (1) ECSP17054181A (enExample)
ES (1) ES2953480T3 (enExample)
FI (1) FI3247707T3 (enExample)
GT (1) GT201700163A (enExample)
HR (1) HRP20230737T1 (enExample)
HU (1) HUE063410T2 (enExample)
IL (6) IL313678A (enExample)
LT (1) LT3247707T (enExample)
MX (3) MX394704B (enExample)
MY (1) MY203427A (enExample)
PE (2) PE20171511A1 (enExample)
PH (2) PH12017501279B1 (enExample)
PL (1) PL3247707T3 (enExample)
PT (1) PT3247707T (enExample)
RS (1) RS64432B1 (enExample)
SG (2) SG11201705928XA (enExample)
SI (1) SI3247707T1 (enExample)
SM (1) SMT202300259T1 (enExample)
TN (1) TN2017000320A1 (enExample)
UA (1) UA119905C2 (enExample)
WO (1) WO2016118774A1 (enExample)
ZA (1) ZA201704777B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
PE20200924A1 (es) 2017-09-13 2020-09-14 Amgen Inc Compuestos de bisamida sustituida que activan el sarcomero cardiaco
HUE067913T2 (hu) 2018-01-19 2024-11-28 Cytokinetics Inc Dihidrobenzofurán és indén analógok mint szív szarkomer gátlók
MY209060A (en) 2018-02-01 2025-06-18 Myokardia Inc Pyrazole compounds and preparation thereof
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
BR112021023074A2 (pt) * 2019-05-19 2022-03-29 Myokardia Inc Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida
WO2021011586A1 (en) * 2019-07-16 2021-01-21 MyoKardia, Inc. Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
EP4146626A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. CHEMOTHERAPEUTIC AGENTS BASED ON HETEROAROMATIC MACROCYCLIC ETHERS
PH12022552787A1 (en) 2020-05-05 2024-03-25 Nuvalent Inc Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
CA3231813A1 (en) 2021-10-01 2023-04-06 Sibao CHEN Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596949A (zh) * 2009-11-11 2012-07-18 大日本住友制药株式会社 8-氮杂双环[3.2.1]辛烷-8-甲酰胺衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250789A1 (en) 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
US7507735B2 (en) * 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596949A (zh) * 2009-11-11 2012-07-18 大日本住友制药株式会社 8-氮杂双环[3.2.1]辛烷-8-甲酰胺衍生物

Also Published As

Publication number Publication date
CL2017001871A1 (es) 2018-04-13
HK1246775A1 (en) 2018-09-14
CN111393414A (zh) 2020-07-10
PE20212253A1 (es) 2021-11-24
MX2022007040A (es) 2022-06-24
AU2023200361B2 (en) 2024-08-22
DK3247707T3 (da) 2023-07-03
TN2017000320A1 (en) 2019-01-16
US20160243100A1 (en) 2016-08-25
IL295547A (en) 2022-10-01
KR20230145504A (ko) 2023-10-17
IL279247A (en) 2021-01-31
PL3247707T3 (pl) 2023-12-11
EA036923B1 (ru) 2021-01-15
BR112017015627B1 (pt) 2022-11-16
AU2023200361A1 (en) 2023-02-23
JP2018502883A (ja) 2018-02-01
EP4234017A3 (en) 2023-10-18
IL253552A0 (en) 2017-09-28
HRP20230737T1 (hr) 2023-10-13
CN118164961A (zh) 2024-06-11
ZA201704777B (en) 2023-07-26
KR102585550B1 (ko) 2023-10-10
AU2020244490A1 (en) 2020-10-29
US9925177B2 (en) 2018-03-27
MX2017009540A (es) 2017-10-20
RS64432B1 (sr) 2023-09-29
NZ734020A (en) 2023-11-24
PE20171511A1 (es) 2017-10-20
EP4234017A2 (en) 2023-08-30
MX394704B (es) 2025-03-24
UA119905C2 (uk) 2019-08-27
DOP2017000166A (es) 2017-10-15
JP6712275B2 (ja) 2020-06-17
KR20170113578A (ko) 2017-10-12
PH12017501279A1 (en) 2018-01-29
HUE063410T2 (hu) 2024-01-28
FI3247707T3 (fi) 2023-08-22
KR20240119163A (ko) 2024-08-06
IL253552B (en) 2019-12-31
PH12021553074A1 (en) 2023-03-06
PT3247707T (pt) 2023-08-31
MY203427A (en) 2024-06-27
CA2974370A1 (en) 2016-07-28
AU2016209200B2 (en) 2020-07-02
AU2024266781A1 (en) 2024-12-12
IL313678A (en) 2024-08-01
KR102688851B1 (ko) 2024-07-29
MX385960B (es) 2025-03-18
WO2016118774A1 (en) 2016-07-28
CA2974370C (en) 2023-10-31
EA201791656A1 (ru) 2017-11-30
AU2020244490B2 (en) 2022-12-01
SG10201913047UA (en) 2020-02-27
GT201700163A (es) 2018-10-18
CN107428719B (zh) 2020-03-27
BR112017015627A2 (pt) 2018-03-13
LT3247707T (lt) 2023-08-25
MX2021010778A (es) 2022-08-11
SI3247707T1 (sl) 2023-10-30
EP3247707A1 (en) 2017-11-29
ECSP17054181A (es) 2019-02-28
IL271034A (en) 2020-01-30
CN107428719A (zh) 2017-12-01
SG11201705928XA (en) 2017-08-30
SMT202300259T1 (it) 2023-09-06
AU2016209200A1 (en) 2017-08-10
ES2953480T3 (es) 2023-11-13
CO2017008398A2 (es) 2017-10-31
EP3247707B1 (en) 2023-05-31
IL286369A (en) 2021-10-31
CR20170370A (es) 2017-10-20
PH12017501279B1 (en) 2023-06-16
DOP2022000172A (es) 2022-09-30

Similar Documents

Publication Publication Date Title
CN111393414B (zh) 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
KR20230051425A (ko) Cd38 억제제
KR20150042269A (ko) N형 칼슘 채널 차단제로서의 치환된 피라졸
US20250275952A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds
HK40027481A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
HK40100462A (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
HK40027481B (zh) 用於治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
HK1246775B (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
CN113015736B (zh) 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
NZ772098B2 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027481

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant